Sinovac Biotech Ltd SVA
Annual
Quarterly
FY2025 · ended Dec 31, 2025 · Revenue $386.01M, +6.8% YoY · Filed Jun 5, 2026
Sinovac Biotech Ltd (SVA) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $386.0 million and a net loss of $198.8 million. Free cash flow was -$561.1 million. As of Dec 31, 2025 it held $6.5 billion in cash and investments and $505.6 million in total debt.
Revenue
$386.01M
+6.8% vs prior year
Net income
$-198.84M
-589.1% vs prior year
Operating cash flow
$-512.18M
-800.3% vs prior year
Free cash flow
$-561.10M
-267.1% vs prior year
EPS
$-0.83
-165.4% vs prior year
Dividend per share
$55.00
Shares outstanding
71.86M
+0.0% vs prior year
Net cash
$5.98B
FY 2025
Operating margin
-127.0%
FY 2025
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- SVA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Antigua and Barbuda
- Headquarters
- Beijing
- SEC filer status
- Accelerated filer
- SEC CIK
- 1084201
- Former names
- NET FORCE SYSTEMS INC (until Jan 13, 2004)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $386.0M | $361.4M | $470.2M | $1.5B | $19.4B |
| Operating income | -$490.1M | -$505.5M | -$714.0M | -$509.0M | $17.6B |
| Net income | -$198.8M | $40.7M | -$120.9M | -$60.0M | $14.1B |
| Diluted EPS | -$0.83 | $1.27 | -$0.19 | $0.20 | $113.44 |
| Operating cash flow | -$512.2M | -$56.9M | $138.6M | -$798.1M | $15.3B |
| Free cash flow | -$561.1M | -$152.9M | $138.6M | -$798.1M | $14.7B |
| Total assets | $8.5B | $12.3B | $13.6B | $14.0B | $16.8B |
| Total liabilities | $2.1B | $2.0B | $2.0B | $1.8B | $3.2B |
| Stockholders' equity | $4.4B | $8.3B | $8.3B | $8.5B | $9.0B |
| Cash and investments | $6.5B | $10.4B | $11.9B | $12.0B | $14.1B |
| Total debt | $505.6M | $391.3M | $299.0M | $70.3M | $138.6M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Aug 17, 2026 | Aug 17, 2026 |
| 6-K | Current report (foreign issuer) | Jul 15, 2026 | Jul 15, 2026 |
| 6-K | Current report (foreign issuer) | Jun 15, 2026 | Jun 15, 2026 |
| 6-K | Current report (foreign issuer) | Jun 5, 2026 | Jun 5, 2026 |
| 20-F | Annual report (foreign issuer) | Jun 5, 2026 | Dec 31, 2025 |
| 6-K | Current report (foreign issuer) | May 29, 2026 | May 29, 2026 |
All 578 Sinovac Biotech Ltd SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.